Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients

Pharmacological Research

Volumn 54, Issue 3, 2006, Pages 181-185

  Baldan, Nicola ^a   Rigotti, Paolo ^a   Furian, Lucrezia ^a   Margani, Giuseppe ^a   Ekser, Burcin ^a   Frison, Laura ^a   De Martin, Sara ^a   Palatini, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Interaction; Pharmacokinetics; Sirolimus; Tacrolimus

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; TACROLIMUS IMX II; UNCLASSIFIED DRUG;

ADULT; AGE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXPOSURE; DRUG WITHDRAWAL; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; PATIENT MONITORING; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADULT; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; SIROLIMUS; TACROLIMUS;

EID: 33746325489     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2006.04.006     Document Type: Article

References (18)

1. Dumont F., Melino M., Staruch M.J., Koprak S.L., Fischer P.A., and Sigal N.H. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J Immunol 144 (1990) 1418-1424
2. Morris R.E., Meiser B.M., Wu J., Shorthouse R., and Wang J. Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 23 (1991) 521-524
3. Vu M.D., Qi S., Xu D., Wu J., Fitzsimmons W.E., Sehgal S.N., et al. Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 64 (1997) 1853-1856
4. Gonwa T., Mendez R., Yang H.C., Weinstein S., Jensik S., Steinberg S., and the Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 75 (2003) 1213-1220
5. Schubert M., Venkataramanan R., Holt D.W., Shaw L.M., McGhee W., Reyes J., et al. Pharmacokinetics of sirolimus and tacrolimus in pediatric transplant patients. Am J Transplant 4 (2004) 767-773
6. Filler G., Womiloju T., Feber J., Lepage N., and Christians U. Adding sirolimus to tacrolimus-based immunosuppression in pediatric renal transplant recipients reduces tacrolimus exposure. Am J Transplant 5 (2005) 2005-2010
7. Hariharan S., Tomlanovich S.J., Filo R.S., Dessimoz M., Wisemandle W., Townsend R.W., et al. Pharmacokinetics (PK) and tolerability of tacrolimus and sirolimus combination therapy in stable renal transplant recipients (abstract). Am J Transplant 1 S1 (2001) 406
8. Undre N.A., Van Hooff J., Christiaans M., Wallemacq P.E., Squifflet J.P., and Stevenson P.J. Pharmacokinetics (PK) of tacrolimus (tac) and rapamycin (rapa) following the administration of different doses of rapa in combination with tac in kidney transplantation (abstract). Proceedings of the 2nd International Congress on Immunosuppression. San Diego (2001) 127
9. McAlister V., Mahalati K., Peltekian K.M., Fraser A., and MacDonald A.S. A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 24 (2002) 346-350
10. Salm P., Taylor P.J., and Pillans P.I. The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients. Clin Ther 22 Suppl. B (2000) 71-85
11. Squifflet J.-P., Vanrenterghem Y., van Hooff J.P., Salmela K., Rigotti P., and the European Tacrolimus/MMF Transplantation Study Group. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 34 (2002) 1584-1586
12. Hesselink D.A., Ngyuen H., Wabbijn M., Smak Gregoor P.J.H., Steyerberg E.W., van Riemsdijk I.C., et al. Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. Br J Clin Pharmacol 56 (2003) 327-330
13. Undre N.A., van Hooff J., Christiaans M., Vanrenterghem Y., Donck J., Heeman U., et al. Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. Transplant Proc 30 (1998) 1299-1302
14. Christians U., Jacobsen W., Benet L.Z., and Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41 (2002) 813-851
15. Lemahieu W.P.D., Maes B.D., Verbeke K., and Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients in cyclosporine vs. tacrolimus vs. sirolimus. Am J Transplant 4 (2004) 1514-1522
16. Bramow S., Ott P., Nielsen F.T., Bangert K., Tygstrup N., and Dalhoff K. Cholestasis and regulation of genes related to drug metabolism and biliary transport in rat liver following treatment with cyclosporine A and sirolimus (rapamycin). Pharmacol Toxicol 89 (2001) 133-139
17. McAlister V., Gao Z., Peltekian K., Dominguez J., Mahalati K., and MacDonald A.S. Sirolimus-tacrolimus combination immunosuppression. Lancet 355 (2000) 376-377
18. MacDonald A.S. Rapamycin in combination with cyclosporine or tacrolimus in liver, pancreas, and kidney transplantation. Transplant Proc 35 Suppl. 3A (2003) 201-208